K. Kosmatopoulos

发表

Identification of HER‐2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors

F. Lemonnier, S. Chouaib, L. Nadler, 2001, European journal of immunology.

Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy1

F. Lemonnier, S. Chouaib, S. Graff-Dubois, 2002, The Journal of Immunology.

In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse

P. Opolon, F. Lemonnier, R. Glück, 2003, British Journal of Cancer.

pH-Triggered Microparticles for Peptide Vaccination

Daniel G. Anderson, R. Langer, W. Haining, 2004, The Journal of Immunology.

Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in “Immune Desert” NSCLC

V. Georgoulias, J. Kinet, M. Avgeris, 2021, Cancers.

CD8 T Cell Responses to Myelin Oligodendrocyte Glycoprotein-Derived Peptides in Humanized HLA-A*0201-Transgenic Mice

R. Liblau, L. Mars, D. Hudrisier, 2007 .

Role of astrocytes in antigen presentation and naive T-cell activation

E. Bettelli, M. Oukka, R. Liblau, 1998, Journal of Neuroimmunology.

Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes

S. Richon, R. Moirand, J. Guillet, 2002, Cancer Immunology, Immunotherapy.

A nonimmunodominant nucleoprotein-derived peptide is presented by influenza A virus-infected H-2b cells.

K. Kosmatopoulos, M. Oukka, N. Riche, 1994, Journal of immunology.

Induction of multiple CD 8 + T cell responses against the inducible Hsp 70 employing an Hsp 70 oligoepitope peptide

F. Lemonnier, I. Miconnet, J. Abastado, 2022 .

CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.

F. Lemonnier, I. Miconnet, K. Kosmatopoulos, 2006, Vaccine.

EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes.

F. Lemonnier, I. Miconnet, S. Chouaib, 2003, Cancer research.

Broad-Spectrum Tumor Immunotherapy-A 12 Tumor Antigens : Implication in a MAGE-A 1 ,-A 2 ,-A 3 ,-A 4 ,-A 6 ,-A 10 , and HLA-A * 0201-Restricted Epitope Shared by Generation of CTL Recognizing an

F. Lemonnier, S. Chouaib, S. Graff-Dubois, 2002 .

Sequential Administration of the Native TERT572 Cryptic Peptide Enhances the Immune Response Initiated by its Optimized Variant TERT572Y in Cancer Patients

D. Mavroudis, V. Georgoulias, E. Papadimitraki, 2011, Journal of immunotherapy.

A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients

S. Graff-Dubois, K. Kosmatopoulos, Jeanne Menez-Jamet, 2016, Oncotarget.

Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001

D. Mavroudis, V. Georgoulias, E. Papadimitraki, 2012, Cancer Immunology, Immunotherapy.

Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination.

J. Manuguerra, I. Vergnon, P. Cordopatis, 1997, Journal of immunology.

CD8 T Cell Responses to Myelin Oligodendrocyte Glycoprotein-Derived Peptides in Humanized HLA-A*0201-Transgenic Mice1

F. Lemonnier, R. Liblau, L. Mars, 2007, The Journal of Immunology.

HLA-A * 0201-Transgenic Mice Peptides in Humanized Oligodendrocyte Glycoprotein-Derived CD 8 T Cell Responses to Myelin

F. Lemonnier, R. Liblau, L. Mars, 2007 .

of April 9 , 2017 . This information is current as HLA-A * 0201-Transgenic Mice Peptides in Humanized Oligodendrocyte Glycoprotein-Derived CD 8 T Cell

F. Lemonnier, D. Hudrisier, J. Bauer, 2007 .

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

J. Soria, F. Lemonnier, I. Miconnet, 2006, Cancer Immunology, Immunotherapy.

A general strategy to enhance immunogenicity of low‐affinity HLA‐A2.1‐associated peptides: implication in the identification of cryptic tumor epitopes

F. Lemonnier, S. Pascolo, S. Tourdot, 2000, European journal of immunology.

HER-2/neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy1

F. Lemonnier, S. Chouaib, L. Nadler, 2002, The Journal of Immunology.

Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines.

K. Kosmatopoulos, Jeanne Menez-Jamet, C. Gallou, 2016, Annals of translational medicine.

A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics.

A. Rossi, C. Gridelli, V. Georgoulias, 2013, Clinical lung cancer.

Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.

V. Georgoulias, D. Mavroudis, P. Cordopatis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.

D. Mavroudis, V. Georgoulias, A. Galanis, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of the Optimized Cryptic Peptide TERT572Y in Patients with Advanced Malignancies

I. Miconnet, P. Kanellou, M. Spyropoulou, 2006, Oncology.

Novel Targets for Broad Spectrum Tumor and hTERT Cryptic Epitopes as neu HER-2 /

F. Lemonnier, S. Chouaib, L. Nadler, 2002 .

Protection against lethal viral infection by vaccination with nonimmunodominant peptides.

J. Manuguerra, I. Vergnon, P. Cordopatis, 1996, Journal of immunology.

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

P. Opolon, J. Davoust, F. Lemonnier, 2004, The Journal of clinical investigation.

Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial

A. Chella, C. Gridelli, V. Georgoulias, 2020, British Journal of Cancer.

High-Affinity HLA-A(*)02.01 Peptides from Parathyroid Hormone-Related Protein Generate In Vitro and In Vivo Antitumor CTL Response Without Autoimmune Side Effects1

M. Sabatino, F. Lemonnier, G. Francini, 2002, The Journal of Immunology.

Effects CTL Response Without Autoimmune Side Generate In Vitro and In Vivo Antitumor Parathyroid Hormone-Related Protein High-Affinity HLA-A ( * ) 02 . 01 Peptides from Pierpaolo Correale

M. Sabatino, F. Lemonnier, G. Francini, 2002 .

Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA‐A*0201‐restricted epitopes

F. Lemonnier, I. Miconnet, J. Abastado, 2004, International journal of cancer.

pH-Triggered Microparticles for Peptide Vaccination1

Daniel G. Anderson, R. Langer, W. Haining, 2004, The Journal of Immunology.

A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.

F. Lemonnier, S. Chouaib, Steven G. Smith, 2007, Cancer research.

Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity.

F. Lemonnier, I. Miconnet, J. Menez, 2006, Vaccine.

Vaccine Targeted to Her-2 / ErbB2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge

F. Lemonnier, S. Chouaib, Steven G. Smith, 2007 .

Safety and immunogenicity of the optimized cryptic peptide TERT572Y in patients with advanced malignancies: A Phase I clinical study

I. Miconnet, M. Spiropoulou, P. Kanellou, 2005 .

Medullary thymic epithelial cells induce tolerance to intracellular proteins.

C. Babinet, M. Cohen-Tannoudji, K. Kosmatopoulos, 1996, Journal of immunology.